Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Catalyst Grant: Innovation in HIV Vaccine and HIV Cure Research

University of Toronto

$100,000.00

How viral membrane components influence epitope recognition by the broadly neutralizing anti-HIV-1 antibody 2F5: potential translation into vaccine design

FY 2012-13

Summary
A share of the 2008 Nobel Prize was awarded to recognize the discovery of Human Immunodeficiency Virus as the cause of the AIDS epidemic. As of today, over 25 million individuals have died from AIDS. Although several treatment options are now available they only moderate the symptoms of the disease, they do not cure. What is really needed is a vaccine. Unfortunately, all efforts to create such a protective means have failed. There are, however, rare individuals, longterm non-progressors, who are able to control HIV and not develop AIDS. Some of them control the virus by producing special antibodies that recognize almost any mutated viable form of the virus. One of these antibodies is called 2F5; it recognizes gp41, the protein responsible for fusion of the viral and host cell membranes, an absolutely crucial step in infection. We have shown, using crystallographic analysis, how this antibody recognizes its target and established that the area of interaction is larger than originally assumed. In collaboration with other laboratories, we also found that an unusually long loop in the protein chain of the antibody is absolutely crucial in neutralizing the virus although its absence is in no way detrimental to its binding to its core epitope. We and others have shown that components of the viral membrane are involved in the antibody-antigen interaction. Using crystallography as well as the new nanodisc technology, we now intend to fully characterize the interaction between antibody and antigen, especially the lipid component of the viral membranes, to provide a starting point for the development of vaccine antigens that will elicit such virus-controlling antibodies.
Program
Catalyst Grant: Innovation in HIV Vaccine and HIV Cure Research
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
276934
Name
Pai Emil F
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
HIV Vaccine and Cure Research
Projecttitle
How viral membrane components influence epitope recognition by the broadly neutralizing anti-HIV-1 antibody 2F5: potential translation into vaccine design
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Catalyst Grant: Innovation in HIV Vaccine and HIV Cure Research
Keyworddelim
Ab Interaction With Membrane Components; Ab-Epitope Complex; Broadly Neutralizing Antibodies; Hiv; Nanodiscs; Protein-Lipid Interactions; Vaccine Design; X-Ray Crystallography
Abstract
A share of the 2008 Nobel Prize was awarded to recognize the discovery of Human Immunodeficiency Virus as the cause of the AIDS epidemic. As of today, over 25 million individuals have died from AIDS. Although several treatment options are now available they only moderate the symptoms of the disease, they do not cure. What is really needed is a vaccine. Unfortunately, all efforts to create such a protective means have failed. There are, however, rare individuals, longterm non-progressors, who are able to control HIV and not develop AIDS. Some of them control the virus by producing special antibodies that recognize almost any mutated viable form of the virus. One of these antibodies is called 2F5; it recognizes gp41, the protein responsible for fusion of the viral and host cell membranes, an absolutely crucial step in infection. We have shown, using crystallographic analysis, how this antibody recognizes its target and established that the area of interaction is larger than originally assumed. In collaboration with other laboratories, we also found that an unusually long loop in the protein chain of the antibody is absolutely crucial in neutralizing the virus although its absence is in no way detrimental to its binding to its core epitope. We and others have shown that components of the viral membrane are involved in the antibody-antigen interaction. Using crystallography as well as the new nanodisc technology, we now intend to fully characterize the interaction between antibody and antigen, especially the lipid component of the viral membranes, to provide a starting point for the development of vaccine antigens that will elicit such virus-controlling antibodies.
Competitiondate
201211
Approvedterm2
1 yr 0 mth
Pinamesdelim
Pai, Emil F
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~